CCA
UROV

Catalyst Capital Advisors’s Urovant Sciences Ltd. UROV Stock Holding History

Catalyst Capital Advisors’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-700
Closed -$8K – 520
2018
Q3 		$8K Buy
+700
New +$8.28K ﹤0.01% 356

Other funds holding UROV

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Catalyst Capital Advisors's UROV Position: Q4 2018 in Review

Catalyst Capital Advisors sold out of Urovant Sciences Ltd. (UROV) in Q4 2018, closing a stake of 700 shares — an estimated $8K sold.

Catalyst Capital Advisors first reported a position in UROV in Q3 2018 and held it in 1 quarter. The position peaked at $8K in Q3 2018. 26 funds tracked by Wall St. Rank hold UROV as of Q4 2018.

  • Catalyst Capital Advisors reported no remaining Urovant Sciences Ltd. position as of Q4 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 700 Urovant Sciences Ltd. shares in Q4 2018, an estimated $8K.
  • Catalyst Capital Advisors first reported a position in Urovant Sciences Ltd. in Q3 2018 and held it in 1 quarter.
  • Catalyst Capital Advisors's Urovant Sciences Ltd. position peaked at $8K in Q3 2018.
  • 26 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q4 2018.

Based on Catalyst Capital Advisors's 13F filing for Q4 2018, filed 7 Feb 2019.